Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study

키워드

참고문헌 (49)

1. Kirkpatrick B, "The NIMHMATRICS consensus statement on negative symptoms", Schizophr Bull, 32, pp.214~219 (2006)
2. De Hert M, "Remission criteria for schizophrenia : evaluation in a large naturalistic cohort", Schizophr Res, 92, pp.68~73 (2007)
3. Hegarty JD, "One hundred years of schizophrenia : a meta-analysis of the outcome literature", Am J Psychiatry, 151, pp.1409~1416 (1994)
4. Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
5. 김희윤, "Prescription Patterns for Patients with Schizophrenia in Korea: A Focus on Antipsychotic Polypharmacy", Clinical Psychopharmacology and Neuroscience, 12(2), pp.128~136 (2014), 대한정신약물학회
6. Correll CU, "Antipsychotic combinations vs monotherapy in schizophrenia : a meta-analysis of randomized controlled trials", Schizophr Bull, 35, pp.443~457 (2009)
7. Canadian Psychiatric Association, "Clinical practice guidelines. Treatment of schizophrenia", Can J Psychiatry, 50(13 Suppl 1), pp.7S~57S (2005)
8. Buchanan RW, "The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements", Schizophr Bull, 36, pp.71~93 (2010)
9. Falkai P, "World Federation of Societies of Biological Psychiatry (WFSBP)guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia", World J Biol Psychiatry, 6, pp.132~191 (2005)
10. Health NCCfM, "The NICE Guidelines on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary care", British Psychological Society, Royal College of Psychiatrists, ~ (2010)
11. Pandurangi AK, "Polypharmacy with second-generation antipsychotics : a review of evidence", J Psychiatr Pract, 14, pp.345~367 (2008)
12. Correll CU, "Does antipsychotic polypharmacy increase the risk for metabolic syndrome?", Schizophr Res, 89, pp.91~100 (2007)
13. Citrome L, "Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients", Psychiatr Serv, 55, pp.1006~1013 (2004)
14. Waddington JL, "Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study", Br J Psychiatry, 173, pp.325~329 (1998)
15. Joukamaa M, "Schizophrenia, neuroleptic medication and mortality", Br J Psychiatry, 188, pp.122~127 (2006)
16. Stahl SM, "Antipsychotic polypharmacy: evidence based or eminence based?", Acta Psychiatr Scand, 106, pp.321~322 (2002)
17. Freudenreich O, "Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations", Acta Psychiatr Scand, 106, pp.323~330 (2002)
18. Barnes TR, "Antipsychotic polypharmacy in schizophrenia : benefits and risks", CNS Drugs, 25, pp.383~399 (2011)
19. Chan J, "Review : combination therapy with non-clozapine atypical antipsychotic medication : a review of current evidence", J Psychopharmacol, 21, pp.657~664 (2007)
20. Suzuki T, "Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone", Hum Psychopharmacol, 23, pp.455~463 (2008)
21. Molina JD, "Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine", Pharmacopsychiatry, 44, pp.142~147 (2011)
22. Miyamoto S, "Treatments for schizophrenia : a critical review of pharmacology and mechanisms of action of antipsychotic drugs", Mol Psychiatry, 10, pp.79~104 (2005)
23. Tenjin T, "Profile of blonanserin for the treatment of schizophrenia", Neuropsychiatr Dis Treat, 9, pp.587~594 (2013)
24. Miura S, "Clinical evaluation of blonanserin for schizophrenia : a randomized controlled study comparing blonanserin with risperidone", Jpn J Clin Psychopharmacol, 11, pp.297~314 (2008)
25. Yang J, "Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial", Clin Neuropharmacol, 33, pp.169~175 (2010)
26. Garcia E, "The efficacy and safety of blonanserin compared with haloperidol in acutephase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study", CNS Drugs, 23, pp.615~625 (2009)
27. Murasaki M, "Clinical evaluation of blonanserin for schizophrenia : a double-blind trial comparing blonanserin with haloperidol", Jpn J Clin Psychopharmacol, 10, pp.2059~2079 (2007)
28. Kishi T, "Blonanserin for schizophrenia:systematic review and meta-analysis of double-blind, randomized, controlled trials", J Psychiatr Res, 47, pp.149~154 (2013)
29. Takaki M, "Efficacy and tolerability of blonanserin in 48 patients with intractable schizophrenia", Acta Neuropsychiatr, 24, pp.380~383 (2012)
30. Lochmann van Bennekom MW, "Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness", J Psychopharmacol, 27, pp.327~336 (2013)
31. Munro J, "Amisulpride augmentation of clozapine : an open non-randomized study in patients with schizophrenia partially responsive to clozapine", Acta Psychiatr Scand, 110, pp.292~298 (2004)
32. Deeks ED, "Blonanserin : a review of its use in the management of schizophrenia", CNS Drugs, 24, pp.65~84 (2010)
33. Preskorn SH, "Clinically important differences in the pharmacokinetics of the ten newer “atypical” antipsychotics: Part 2. Metabolism and elimination", J Psychiatr Pract, 18, pp.361~368 (2012)
34. Vermeir M, "Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans", Drug Metab Dispos, 36, pp.769~779 (2008)
35. Gardner DM, "International consensus study of antipsychotic dosing", Am J Psychiatry, 167, pp.686~693 (2010)
36. Honer WG, "Clozapine alone versus clozapine and risperidone with refractory schizophrenia", N Engl J Med, 354, pp.472~482 (2006)
37. Freudenreich O, "Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial", Schizophr Res, 92, pp.90~94 (2007)
38. Fleischhacker WW, "Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial", Int J Neuropsychopharmacol, 13, pp.1115~1125 (2010)
39. Friedman JI, "Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy", Neuropsychopharmacology, 36, pp.1289~1295 (2011)
40. Gunduz-Bruce H, "Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia", Schizophr Res, 143, pp.344~347 (2013)
41. Chang JS, "Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia:an 8-week, randomized, double-blind, placebo-controlled trial", J Clin Psychiatry, 69, pp.720~731 (2008)
42. Weiner E, "Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine", Neuropsychopharmacology, 35, pp.2274~2283 (2010)
43. Cipriani A, "Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial", J Clin Psychopharmacol, 33, pp.533~537 (2013)
44. Assion HJ, "Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebocontrolled trial", Pharmacopsychiatry, 41, pp.24~28 (2008)
45. Taylor DM, "Augmentation of clozapine with a second antipsychotic-a meta-analysis", Acta Psychiatr Scand, 125, pp.15~24 (2012)
46. Fleischhacker WW, "Critical review of antipsychotic polypharmacy in the treatment of schizophrenia", Int J Neuropsychopharmacol, 17, pp.1083~1093 (2014)
47. Jessurun JG, "The effect of psychotropic medications on the occurrence of constipation in hospitalized psychiatric patients", J Clin Psychopharmacol, 33, pp.587~590 (2013)
48. Kane JM, "The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary", J Clin Psychiatry, 64(Suppl 12), pp.5~19 (2003)
49. Hasan A, "World Federation of Societies of Biological Psychiatry (WFSBP)Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance", World J Biol Psychiatry, 13, pp.318~378 (2012)

관련 논문AI추천